Novartis will make waves in gene therapy, says head of biomedical research
This article was originally published in Scrip
Executive Summary
Novartis, unlike several of its big pharma peers, has itself a healthy looking pipeline now and for the foreseeable future – allowing the company the luxury of "being a bit choosy" when it comes to selecting investments.